Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy

Supplemental Digital Content is available in the text Introduction: Identification of residual disease after neuroendocrine tumor (NET) resection is critical for management. Post-surgery imaging is insensitive, expensive, and current biomarkers ineffective. We evaluated whether the NETest, a multigene liquid biopsy blood biomarker, correlated with surgical resection and could predict recurrence. Methods: Multicenter evaluation of NET resections over 24 months (n = 103): 47 pancreas, 26 small bowel, 26 lung, 2 appendix, 1 duodenum, 1 stomach. Surgery: R0 (83), R1/R2 (20). One millilitre of blood was collected at D0 and posroperative day (POD) 30. Transcript quantification by polymerase chain reaction (normal: ≤20), CgA by NEOLISA (normal ≤108 ng/mL). Standard-of-care (SoC) follow-up costs were calculated and compared to POD30 NETest-stratification approach. Analyses: Wilcoxon-paired test, Chi-square test. Results: D0 biomarkers: NETest: 103 of 103 (100%)-positive, whereas 23 of 103 (22%) were CgA-positive (Chi-square = 78, P < 0.0001). In the R0 group, the NETest decreased 59 ± 28 to 26 ± 23 (P < 0.0001); 36% (30/83) remained elevated. No significant decrease was evident for CgA. In the R1/R2 group the NETest decreased but 100% remained elevated. CgA levels did not decrease. An elevated POD30 NETest was present in R0 and 25 (83%) developed radiological recurrences. Normal score R0 s (n = 53) did not develop recurrence (Chi-square = 56, P < 0.0001). Recurrence prediction was 94% accurate with the NETest. Cost evaluation: Using the NETest to stratify postoperative imaging resulted in a cost-savings of 42%. Conclusion: NETest diagnosis is more accurate than CgA (100% vs 22%). Surgery significantly decreased NETest. An elevated POD30 NETest predicted recurrence with 94% accuracy and post-surgical POD30 NETest follow-up stratification decreased costs by 42%. CgA had no surgical utility. Further studies would define the accuracy and cost-effectiveness of the NETest in the detection of postoperative recurrent disease.

[1]  J. Wisnivesky,et al.  Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients , 2021, BMC cancer.

[2]  C. Auernhammer,et al.  Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors , 2021, Diagnostics.

[3]  M. Caplin,et al.  Diagnostic and therapeutic advances in neuroendocrine tumours , 2020, Nature Reviews Endocrinology.

[4]  B. Kos-Kudła,et al.  NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis , 2020, Endocrine connections.

[5]  I. Drozdov,et al.  Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest , 2020, Neuroendocrinology.

[6]  B. Kos-Kudła,et al.  Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience , 2020, Neuroendocrinology.

[7]  M. Falconi,et al.  Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. Califano,et al.  A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  P. Jänne,et al.  Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. , 2019, Lung cancer.

[10]  P. Manoharan,et al.  Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice , 2019, Journal of clinical medicine.

[11]  S. Larson,et al.  PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype? , 2019, Clinical and Translational Imaging.

[12]  I. Drozdov,et al.  Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis , 2019, PloS one.

[13]  M. Neary,et al.  Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome , 2019, BMC cancer.

[14]  J. Carpten,et al.  Multiparametric liquid biopsy analysis in metastatic prostate cancer. , 2019, JCI insight.

[15]  W. Verbeek,et al.  Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study , 2018, Front. Endocrinol..

[16]  I. Modlin,et al.  Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease , 2018, The Journal of clinical endocrinology and metabolism.

[17]  J. Strosberg.  177Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors , 2018, Oncotarget.

[18]  K. Öberg.  The Genesis of the Neuroendocrine Tumors Concept: From Oberndorfer to 2018. , 2018, Endocrinology and metabolism clinics of North America.

[19]  R. Salem,et al.  Assessment of NETest Clinical Utility in a U.S. Registry-Based Study. , 2018, The oncologist.

[20]  Hideaki Takahashi,et al.  Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors. , 2018, The oncologist.

[21]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[22]  I. Drozdov,et al.  The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression† , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[23]  Reena Philip,et al.  FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation , 2017, The oncologist.

[24]  A. Darzi,et al.  Surgical Management of Patients with Neuroendocrine Neoplasms of the Appendix: Appendectomy or More , 2017, Neuroendocrinology.

[25]  M. Falconi,et al.  Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications , 2017, The Journal of clinical endocrinology and metabolism.

[26]  Xihong Lin,et al.  Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors , 2017, The oncologist.

[27]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[28]  I. Drozdov,et al.  NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive , 2016, Neuroendocrinology.

[29]  R. Kianmanesh,et al.  ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update , 2016, Neuroendocrinology.

[30]  D. Metz,et al.  Consensus on biomarkers for neuroendocrine tumour disease. , 2015, The Lancet. Oncology.

[31]  C. Claussen,et al.  Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

[32]  B. Wiedenmann,et al.  ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update , 2011, Neuroendocrinology.

[33]  I. Modlin,et al.  Siegfried oberndorfer and the evolution of carcinoid disease. , 2007, Archives of surgery.

[34]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[35]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[36]  A. Colao,et al.  Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. , 2018, Endocrine-related cancer.

[37]  I. Drozdov,et al.  Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. , 2008, International journal of oncology.

[38]  S. Oberndorfer.  Karzinoide Tumoren des Dunndarms , 1907 .